{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.6","value":"7950"},{"groupId":"OG001","spread":"106","value":"8320"},{"groupId":"OG002","spread":"117","value":"19600"},{"groupId":"OG003","spread":"11.4","value":"26200"},{"groupId":"OG004","spread":"152","value":"3180"},{"groupId":"OG005","spread":"370","value":"3280"},{"groupId":"OG007","spread":"80.2","value":"12400"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"description":"PK: AUCtau of LY3475070","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG000","title":"Cohort A - 150mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG001","title":"Cohort A - 300mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG002","title":"Cohort A - 300mg BID LY3475070"},{"description":"Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG003","title":"Cohort A - 600mg QD LY3475070"},{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG004","title":"Cohort B - 150mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG005","title":"Cohort B - 150mg BID LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG006","title":"Cohort B - 300mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study","id":"OG007","title":"Cohort B - 300mg BID LY3475070 + Pembrolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants in phase1a who received LY3475070 and had intensively sampled evaluable PK data on cycle 2 day 1. For \"Cohort B - 300mg QD LY3475070 + pembrolizumab,\" the participant has not received the treatment on cycle 2 day 1, and did not meet the analysis criteria. Thus, zero participants were analysed.","reportingStatus":"POSTED","timeFrame":"Cycle 2 Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 24 hours post-dose for the QD arms, Pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose for the BID arms)","title":"PK: Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCtau) of LY3475070","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}